<DOC>
	<DOC>NCT00696995</DOC>
	<brief_summary>This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions when initiating or switching to insulin therapy with NovoMix® 30 in subjects with type 2 diabetes under normal clinical practice conditions</brief_summary>
	<brief_title>An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Patients with Type 2 diabetes Insulinnaive or previously treated by basal only insulin therapy Patients who are unlikely to comply with the protocol Pregnancy or breastfeeding or intention of becoming pregnant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>